A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust in Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation

被引：0

作者：

Campbell, Veronica ^{[1
]}

Kelleher, Joseph ^{[1
]}

Chen, Jesse ^{[1
]}

Gollob, Jared ^{[1
]}

Ji, Nan ^{[1
]}

Klaus, Christine ^{[1
]}

Loh, Christine ^{[1
]}

Mayo, Michelle ^{[1
]}

McDonald, Alice ^{[1
]}

Rong, Haojing ^{[1
]}

Rusin, Scott ^{[1
]}

Sharma, Kirti ^{[1
]}

Weiss, Matt ^{[1
]}

Yuan, Karen ^{[1
]}

Walker, Duncan ^{[1
]}

Zheng, Xiaozhang ^{[1
]}

Slavin, Anthony ^{[1
]}

Mainolfi, Nello ^{[1
]}

机构：

[1] Kymera Therapeut, Cambridge, MA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1768

引用

页数：2

共 8 条

[1] IRAK4 in TLR/IL-1R signaling: Possible clinical applications
Li, Xiaoxia
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (03) : 614 - 618
[2] Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling
Su-Chang Lin
Yu-Chih Lo
Hao Wu
Nature, 2010, 465 : 885 - 890
[3] R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Chen, Yan
Yi, Sothy
Markovtsov, Vadim
Samant, Bhushan
Chow, Andrew
Masuda, Esteban
Shaw, Simon
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2605 - 2606
[4] IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Teng, Grace
Fung, Thomas
Mocciaro, Annamaria
Llapashtica, Ceyda
Hammond, Angie
Gurgel, Jesse
Huang, Zhiyu
Mouchess, Maria
Gorney, Vanessa
Minto, Wesley
Mohanan, Sunish
Schrier, Adam
Palmer, Wylie
Borodovsky, Alexandra
Min-oo, Gundula
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1936 - 1937
[5] KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition
Kelleher, Joseph F.
Campbell, Veronica
Chen, Jesse
Gollob, Jared
Ji, Nan
Kamadurai, Hari
Klaus, Christine
Li, Henry
Loh, Christine
McDonald, Alice
Rong, Haojing
Rusin, Scott
Sharma, Kirti
Vigil, Dominico
Walker, Duncan
Weiss, Matt
Yuan, Karen
Zhang, Yi
Audoly, Laurent
Mainolfi, Nello
CANCER RESEARCH, 2019, 79 (13)
[6] BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models
Li, Zhuo
Qu, Liang
Chen, Xin
Xue, Liu
Li, Jie
Liu, Qi
Sun, Jian
Sun, Hanzi
Chen, Yun
Xie, Yuanyuan
Wang, Wanyi
Zhu, Lin
Wang, Penghao
Zhou, Xiaosui
Hou, Hongjia
Chen, Jie
Liu, Xinyi
Zhang, Yilu
Liu, Ning
Liang, Xinyi
Zhang, Shuo
Tang, Xiaoyan
Song, Jing
Zhang, Tong
Song, Xiaomin
Liu, Xuesong
Li, Kang
Huang, Chichi
CANCER RESEARCH, 2024, 84 (06)
[7] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Hansen, Erica
Quivoron, Cyril
Straley, Kim
Lemieux, Rene M.
Popovici-Muller, Janeta
Sadrzadeh, Hossein
Fathi, Amir T.
Gliser, Camelia
David, Muriel
Saada, Veronique
Micol, Jean-Baptiste
Bernard, Olivier
Dorsch, Marion
Yang, Hua
Su, Michael
Agresta, Sam
de Botton, Stephane
Penard-Lacronique, Virginie
Yen, Katharine
BLOOD, 2014, 124 (21)
[8] Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)
Axten, Jeffrey M.
Medina, Jesus R.
Feng, Yanhong
Shu, Arthur
Romeril, Stuart P.
Grant, Seth W.
Li, William Hoi Hong
Heerding, Dirk A.
Minthorn, Elisabeth
Mencken, Thomas
Atkins, Charity
Liu, Qi
Rabindran, Sridhar
Kumar, Rakesh
Hong, Xuan
Goetz, Aaron
Stanley, Thomas
Taylor, J. David
Sigethy, Scott D.
Tomberlin, Ginger H.
Hassell, Annie M.
Kahler, Kirsten M.
Shewchuk, Lisa M.
Gampe, Robert T.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (16) : 7193 - 7207

← 1 →